STU3 Candidate

This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

V3-substanceAdminSubstitution.cs.xml

Raw XML (canonical form)

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="v3-substanceAdminSubstitution"/>
  <meta>
    <lastUpdated value="2016-11-11T00:00:00.000+11:00"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p>Release Date: 2016-11-11</p>

      <table class="grid">
 
        <tr>
          <td>
            <b>Level</b>
          </td>
          <td>
            <b>Code</b>
          </td>
          <td>
            <b>Display</b>
          </td>
          <td>
            <b>Definition</b>
          </td>
        </tr>
 
        <tr>
          <td>1</td>
          <td>
            <span style="color: grey">
              <i>(_ActSubstanceAdminSubstitutionCode)</i>
            </span> 
            <b>
              <i>Abstract</i>
            </b>
          </td>
          <td>
            <a name="_ActSubstanceAdminSubstitutionCode"> </a>
          </td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product that may potentially have different ingredients, but having the same biological
               and therapeutic effects.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  E
            <a name="E"> </a>
          </td>
          <td>equivalent</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               bioequivalent and therapeutically equivalent product.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    EC
            <a name="EC"> </a>
          </td>
          <td>equivalent composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted with another product that
               is a:
            <br/>

                        
                           pharmaceutical alternative containing the same active ingredient
               but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
               strength, dosage form and route of administration
                        
                        
                           Examples: 
                        
            <br/>

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
               for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      BC
            <a name="BC"> </a>
          </td>
          <td>brand composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted between equivalent Brands
               but not Generics
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      G
            <a name="G"> </a>
          </td>
          <td>generic composition</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               equivalent Generics but not Brands
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    TE
            <a name="TE"> </a>
          </td>
          <td>therapeutic alternative</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product having the same therapeutic objective and safety profile.
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           ranitidine for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TB
            <a name="TB"> </a>
          </td>
          <td>therapeutic brand</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Brands but not Generics
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Zantac for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TG
            <a name="TG"> </a>
          </td>
          <td>therapeutic generic</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Generics but not Brands
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Ranitidine  for cimetidine
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  F
            <a name="F"> </a>
          </td>
          <td>formulary</td>
          <td>
                        
                           Description: This substitution was performed or is permitted
               based on formulary guidelines. 
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  N
            <a name="N"> </a>
          </td>
          <td>none</td>
          <td>
                        No substitution occurred or is permitted.
            <br/>

                     
          </td>
        </tr>

      </table>

    </div>
  </text>
  <url value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.5.1070"/>
  </identifier>
  <version value="2016-11-11"/>
  <name value="v3 Code System substanceAdminSubstitution"/>
  <status value="active"/>
  <experimental value="false"/>
  <publisher value="HL7, Inc"/>
  <contact>
    <telecom>
      <system value="url"/>
      <value value="http://hl7.org"/>
    </telecom>
  </contact>
  <date value="2016-11-11T00:00:00+11:00"/>
  <description value=" Identifies what sort of change is permitted or has occurred between the therapy that
     was ordered and the therapy that was/will be provided."/>
  <caseSensitive value="true"/>
  <valueSet value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/>
  <hierarchyMeaning value="is-a"/>
  <content value="complete"/>
  <property>
    <code value="notSelectable"/>
    <uri value="http://hl7.org/fhir/concept-properties#notSelectable"/>
    <description value="Indicates that the code is abstract - only intended to be used as a selector for other
       concepts"/>
    <type value="boolean"/>
  </property>
  <concept>
    <code value="_ActSubstanceAdminSubstitutionCode"/>
    <display value="ActSubstanceAdminSubstitutionCode"/>
    <definition value="Description: Substitution occurred or is permitted with another product that may potentially
       have different ingredients, but having the same biological and therapeutic effects."/>
    <property>
      <code value="notSelectable"/>
      <valueBoolean value="true"/>
    </property>
    <concept>
      <code value="E"/>
      <display value="equivalent"/>
      <definition value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically
         equivalent product."/>
      <concept>
        <code value="EC"/>
        <display value="equivalent composition"/>
        <definition value="Description:                                                    Substitution occurred
           or is permitted with another product that is a:                                      
                          pharmaceutical alternative containing the same active ingredient but is
           formulated with different salt, ester                            pharmaceutical equivalent
           that has the same active ingredient, strength, dosage form and route of administration
                                                                                        Examples:
                                                                                                
                                   Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin
           Stearate                                                           Pharmaceutical equivalent:
           Lisonpril for Zestril"/>
        <concept>
          <code value="BC"/>
          <display value="brand composition"/>
          <definition value="Description:                                                    Substitution occurred
             or is permitted between equivalent Brands but not Generics                           
                                       Examples:                                                  
                                          Zestril  for Prinivil                            Coumadin
             for Jantoven"/>
        </concept>
        <concept>
          <code value="G"/>
          <display value="generic composition"/>
          <definition value="Description: Substitution occurred or is permitted between equivalent Generics but not
             Brands                                                      Examples:                
                                                                            Lisnopril (Lupin Corp)
             for Lisnopril (Wockhardt Corp)"/>
        </concept>
      </concept>
      <concept>
        <code value="TE"/>
        <display value="therapeutic alternative"/>
        <definition value="Description: Substitution occurred or is permitted with another product having the same
           therapeutic objective and safety profile.                                            
                    Examples:                                                                   
                       ranitidine for Tagamet"/>
        <concept>
          <code value="TB"/>
          <display value="therapeutic brand"/>
          <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
             Brands but not Generics &gt;                            Examples:                    
                                                                        Zantac for Tagamet"/>
        </concept>
        <concept>
          <code value="TG"/>
          <display value="therapeutic generic"/>
          <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
             Generics but not Brands &gt;                            Examples:                    
                                                                        Ranitidine  for cimetidine"/>
        </concept>
      </concept>
    </concept>
    <concept>
      <code value="F"/>
      <display value="formulary"/>
      <definition value="Description: This substitution was performed or is permitted based on formulary guidelines."/>
    </concept>
    <concept>
      <code value="N"/>
      <display value="none"/>
      <definition value="No substitution occurred or is permitted."/>
    </concept>
  </concept>
</CodeSystem>

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.